Expression profiling of CC531 colon carcinoma cells reveals similar regulation of β-catenin target genes by both butyrate and aspirin

International Journal of Cancer

Volumn 106, Issue 2, 2003, Pages 187-197

  Germann, Anja ^a   Dihlmann, Susanne ^a   Hergenhahn, Manfred ^b   Von Knebel Doeberitz, Magnus ^a   Koesters, Robert ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

catenin; 1, 2 dimethylhydrazine; Affymetrix; Aspirin; Butyrate; CC531; Chemoprevention; Colon; Gene expression profiling; Histone deacetylase inhibitor; Ki ras; Microarray; Nonsteroidal anti inflammatory drug

Indexed keywords

ACETYLSALICYLIC ACID; AMINO ACID; ANTINEOPLASTIC AGENT; BETA CATENIN; BUTYRIC ACID; CYCLIN D1; CYCLIN E; FOLLISTATIN; HERMES ANTIGEN; HISTONE DEACETYLASE INHIBITOR; ISOLEUCINE; MYC PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN C FOS; PROTEIN FOS; PROTEIN FOS11; RAS PROTEIN; THREONINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; COLON CANCER; COLON CARCINOGENESIS; DNA MICROARRAY; DRUG RESPONSE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE MUTATION; METASTASIS; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; ONCOGENE RAS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ASPIRIN; BETA CATENIN; BLOTTING, NORTHERN; BUTYRATES; CELL DIVISION; COLONIC NEOPLASMS; CYTOSKELETAL PROTEINS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; RNA, NEOPLASM; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0038155177     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11215     Document Type: Article

References (65)

1. Wingo PA, Tong T, Bolden S. Cancer statistics. 1995. CA Cancer J Clin 1995;45:8-30.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
3. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
4. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B. Prevalence of ras mutations in human colorectal cancers. Nature 1987;327:293-7.
5. Froggatt NJ, Leveson SH, Garner RC. Low frequency and late occurrence of p53 and dcc aberrations in colorectal tumours. J Cancer Res Clin Oncol 1995;121:7-15.
6. Erdman SH, Wu HD, Hixson LJ, Ahnen DJ, Gerner EW. Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats. Mol Carcinog 1997;19:137-44.
7. Koesters R, Hans MA, Benner A, Prosst R, Boehm J, Gahlen J, Doeberitz MK. Predominant mutation of codon 41 of the beta-catenin proto-oncogene in rat colon tumors induced by 1,2-dimethylhydrazine using a complete carcinogenic protocol. Carcinogenesis 2001;22:1885-90.
8. Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V, Niggli F, Briner J, von Knebel Doeberitz M. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 1999;59:3880-2.
9. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
10. Davis AE, Patterson F. Aspirin reduces the incidence of colonic carcinoma in the dimethylhydrazine rat animal model. Aust N Z J Med 1994;24:301-3.
11. Mereto E, Frencia L, Ghia M. Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colon by 1,2-dimethylhydrazine. Cancer Lett 1994;76:5-9.
12. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 2002;3:166-74.
13. Dihlmann S, Siermann A, von Knebel Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate β-catenin/TCF-4 signaling. Oncogene 2001;20:645-53.
14. Archer SY, Hodin RA. Histone acetylation and cancer. Curr Opin Genet Dev 1999;9:171-4.
15. Csordas A. Butyrate, aspirin and colorectal cancer. Eur J Cancer Prev 1996;5:221-31.
16. Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998;95:6791-6.
17. Medina V, Afonso JJ, Alvarez-Arguelles H, Hernandez C, Gonzalez F. Sodium butyrate inhibits carcinoma development in a 1,2-dimethylhydrazine-induced rat colon cancer. JPEN J Pareter Enteral Nutr 1998;22:14-7.
18. Marquet RL, Westbroek DI, Jeekel J. Interferon treatment of a transplantable colon adenocarcinoma; importance of tumor site. Br J Cancer 1984;33:689-92.
19. Pross M, Lippert H, Mantke R, Kruger S, Gunther T, Marusch F, Halangk W, Schulz HU. A proteinase inhibitor decreases tumor growth in a laparoscopic rat model. Surg Endosc 2001;15:882-5.
20. van Etten B, ten Hagen TL, de Vries MR, Ambagtsheer G, Huet T, Eggermont AM. Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras. Br J Cancer 2002;86:436-42.
21. Kuppen PJ, Basse PH, Goldfarb RH, Van De Velde CJ, Fleuren GJ, Eggermont AM. The infiltration of experimentally induced lung metastases of colon carcinoma CC531 by adoptively transferred interleukin-2-activated natural killer cells in Wag rats. Int J Cancer 1994;56:574-9.
22. Lopes Cardozo AM, Gupta A, Koppe MJ, Meijer S, van Leeuwen PA, Beelen RJ, Bleichrodt RP. Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats. Eur J Surg Oncol 2001;27:359-63.
23. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-8.
24. Wong NA, Pignatelli M. Beta-catenin - a linchpin in colorectal carcinogenesis? Am J Pathol 2002;160:389-401.
25. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Buhr HJ, Hanski C. Target genes of beta-catenin/T-cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999;96:1603-8.
26. Willert J, Epping M, Pollack JR, Brown PO, Nusse R. A transcriptional response to Wnt protein in human embryonic carcinoma cells. Bio Med Central Dev Biol 2002;2:8.
27. Malumbres M, Pellicer A. RAS pathways to cell cycle control and cell transformation. Front Biosci 1998;3:887-912.
28. 1 progression in NIH 3T3 cells. Mol Cell Biol 1995;15:3654-63.
29. Winston JT, Coats SR, Wang YZ, Pledger WJ. Regulation of the cell cycle machinery by oncogenic ras. Oncogene 1996;12:127-34.
30. Mechta F, Lallemand D, Pfarr CM, Yaniv M. Transformation by ras modifies AP1 composition and activity. Oncogene 1997;14:837-47.
31. Jamal HH, Cano-Gauci DF, Buick RN, Filmus J. Activated ras and src induce CD44 overexpression in rat intestinal epithelial cells. Oncogene 1994;9:417-23.
32. Shao J, Sheng H, DuBois RN. Peroxisome proliferator-activated receptors modulate K-ras-mediated transformation of intestinal epithelial cells. Cancer Res 2002;62:3282-8.
33. Allgayer H, Wang H, Shirasawa S, Sasazuki T, Boyd D. Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line downregulates urokinase receptor expression and plasminogen-dependent proteolysis. Br J Cancer 1999;80:1884-91.
34. Yamamoto H, Itoh F, Senota A, Adachi Y, Yoshimoto M, Endoh T, Hinoda Y, Yachi A, Imai K. Expression of matrix metalloproteinase matrilysin (MMP-7) was induced by activated Ki-ras via AP-1 activation in SW1417 colon cancer cells. J Clin Lab Anal 1995;9:297-301.
35. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-80.
36. Francis-Lang H, Zannini M, De Felice M, Berlingieri MT, Fusco A, Di Lauro R. Multiple mechanisms of interference between transformation and differentiation in thyroid cells. Mol Cell Biol 1992;12:5793-80.
37. Guo X, Zhang YP, Mitchell DA, Denhardt DT, Chambers AF. Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. Mol Cell Biol 1995;15:476-87.
38. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002;3:101-28.
39. Mariadason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 2000;60:4561-72.
40. Iacomino G, Tecce MF, Grimaldi C, Tosto M, Russo GL. Transcriptional response of a human colon adenocarcinoma cell line to sodium butyrate. Biochem Biophys Res Commun 2001;285:1280-9.
41. Iizaka M, Furukawa Y, Tsunoda T, Akashi H, Ogawa M, Nakamura Y. Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun 2002;292:498-512.
42. Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 2001;8:1505-11.
43. Shimokawa T, Smith WL. Prostaglandin endoperoxide synthase. The aspirin acetylation region. J Biol Chem 1992;267:12387-92.
44. Lecomte M, Laneuville O, Ji C, DeWitt DL, Smith WL. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 1994;269:13207-15.
45. Stark LA, Din FV, Zwacka RM, Dunlop MG. Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J 2001;15:1273-5.
46. Choi KC, Kang SK, Nathwani PS, Cheng KW, Auersperg N, Leung PC. Differential expression of activin/inhibin subunit and activin receptor mRNAs in normal and neoplastic ovarian surface epithelium (OSE). Mol Cell Endocrinol 2001;174:99-110.
47. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC. The regulation of apoptosis by activin and transforming growth factor-beta in early neoplastic and tumorigenic ovarian surface epithelium. J Clin Endocrinol Metab 2001;86:2125-35.
48. Risbridger GP, Mellor SL, McPherson SJ, Schmitt JF. The contribution of inhibins and activins to malignant prostate disease. Mol Cell Endocrinol 2001;180:149-53.
49. Rossmanith W, Chabicovsky M, Grasl-Kraupp B, Peter B, Schausberger E, Schulte-Hermann R. Follistatin overexpression in rodent liver tumors: a possible mechanism to overcome activin growth control. Mol Carcinog 2002;35:1-5.
50. Yuen MF, Norris S, Evans LW, Langley PG, Hughes RD. Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis. Scand J Gastroenterol 2002;37:233-8.
51. Tabuchi Y, Arai Y, Kondo T, Takeguchi N, Asano S. Identification of genes responsive to sodium butyrate in colonic epithelial cells. Biochem Biophys Res Commun 2002;293:1287-94.
52. Kondoh N, Oikawa T, Satoh C, Kuzumaki N. Effects of sodium butyrate on the rearranged c-myc expression in mouse plasmacytoma cells. Exp Cell Res 1991;196:146-9.
53. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-74.
54. Alessi DR, Smythe C, Keyse SM. The human CL100 gene encodes a Tyr/Thr-protein phosphatase which potently and specifically inactivates MAP kinase and suppresses its activation by oncogenic ras in Xenopus oocyte extracts. Oncogene 1993;8:2015-20.
55. Manzano RG, Montuenga LM, Dayton M, Dent P, Kinoshita I, Vicent S, Gardner GJ, Nguyen P, Choi YH, Trepel J, Auersperg N, Birrer MJ. CL100 expression is downregulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene 2002;21:4435-47.
56. Wang A, Yoshimi N, Suzui M, Yamauchi A, Tarao M, Mori H. Different expression patterns of cyclins A, D1 and E in human colorectal cancer. J Cancer Res Clin Oncol 1996;122:122-6.
57. Li JQ, Miki H, Ohmori M, Wu F, Funamoto Y. Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma. Hum Pathol 2001;32:945-53.
58. Sugio K, Kurata S, Sasaki M, Soejima J, Sasazuki T. Differential expression of c-myc gene and c-fos gene in premalignant and malignant tissues from patients with familial polyposis coli. Cancer Res 1988;48:4855-61.
59. Souleimani A, Asselin C. Regulation of c-fos expression by sodium butyrate in the human colon carcinoma cell line Caco-2. Biochem Biophys Res Commun 1993;193:330-6.
60. Huang RP, Liu C, Fan Y, Mercola D, Adamson ED. Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain. Cancer Res 1995;55:5054-62.
61. Huang RP, Fan Y, de Belle I, Niemeyer C. Gottardis MM, Mercola D, Adamson ED. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer 1997;72:102-9.
62. Tice DA, Soloviev I, Polakis P. Activation of the Wnt pathway interferes with serum response element-driven transcription of immediate early genes. J Biol Chem 2002;277:6118-23.
63. Liu C, Adamson E, Mercola D. Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1. Proc Natl Acad Sci USA 1996;93:11831-6.
64. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev 1996;7:93-102.
65. Kim DG, You KR, Liu MJ, Choi YK, Won YS. GADD153-mediated anticancer effects of N-(4-hydroxyphenyl)retinamide on human hepatoma cells. J Biol Chem 2002;277:38930-8.